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Abstract
The renin–angiotensin system plays an important role in the pathogenesis of cardiovascular disease. Cloning of the human genes
coding for the angiotensin-converting enzyme, angiotensinogen, and angiotensin II type 1 receptor has led to the discovery of several
 .polymorphisms, which may be implicated in the pathogenesis of cardiovascular disease. The deletionrinsertion Dr I polymorphism of
the angiotensin-converting enzyme gene is associated with hypertension in men, left ventricular hypertrophy in untreated hypertensive
patients, various atherosclerotic cardiovascular complications, and microvascular disorders. The M235T polymorphism of the an-
giotensinogen gene may be associated with a higher risk of hypertension. The A1166C polymorphism of the angiotensin II type 1
receptor gene is probably correlated with hypertension and through an epistatic interaction with the Dr I polymorphism of the
angiotensin-converting enzyme gene possibly also with coronary heart disease. Several other gene polymorphisms, in particular those in
the promoter area of the angiotensinogen gene, have been studied in relation to cardiovascular disease. Based on the insights gained from
the reports summarized in this review article, population-based genetic studies of nuclear families are currently being conducted in
Belgium and in the People’s Republic of China with blood pressure and hypertension as the main outcome variables. q 2000 Elsevier
Science B.V. All rights reserved.
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1. Introduction
The renin–angiotensin system, a two-enzyme cascade,
plays an important role in the regulation of blood pressure,
fluid balance, and electrolyte homeostasis Sealey et al.,
.1995; Hall et al., 1986 and in the pathogenesis of cardio-
 .vascular disease Dzau, 1993; Campbell, 1987 . The initial
enzyme, renin, cleaves its substrate, angiotensinogen, to
angiotensin I, a decapeptide. Angiotensin I undergoes a
second cleavage, mainly by tissue-bound angiotensin-con-
 .verting enzyme and serine proteinase Urata et al., 1996 ,
 .to generate angiotensin II an octapeptide , which via the
angiotensin II type 1 receptor acts as a potent vasocon-
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strictor and aldosterone stimulating peptide. The an-
giotensin-converting enzyme also inactivates the nonapep-
tide bradykinin and blocks the tissue kallikrein system.
Inhibition of the angiotensin-converting enzyme and antag-
onism of the angiotensin II type 1 receptor decrease blood
pressure in hypertensive patients MacKay et al., 1996;
.Azizi et al., 1997 , and more importantly also prevent
mortality and morbidity in patients with symptomatic or
asymptomatic congestive heart failure Sharpe et al., 1988,
.1991; Pfeffer et al., 1992 , acute myocardial infarction
ACE Inhibitor Myocardial Infarction Collaborative Group,
.  .1998 , or diabetic nephropathy Lewis et al., 1993 .
Cloning of the human genes coding for the angio-
 .tensin-converting enzyme Rigat et al., 1990, 1992 , an-
 .giotensinogen Jeunemaitre et al., 1992 , and the an-
 .giotensin II type 1 receptor Bonnardeaux et al., 1994 has
 .led to the discovery of several polymorphisms Table 1 ,
which may play a role as risk factors for cardiovascular
disorders, such as hypertension, coronary heart disease, or
cardiomyopathy. Among these genetic mutations, the an-
giotensin-converting enzyme gene deletionrinsertion Dr
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Table 1
Polymorphisms of genes coding for the proteins of the renin–angiotensin system
Gene cytogenetic Polymorphism Location Change in DNA Change in protein Reference
.map location in gene
 .Angiotensin-converting Dr I intron 16 287 bp concentration Rigat et al., 1990
 .enzyme 17q22-q24 deletion™ insertion
X( )  .4656 CT 3 UTR CTCT™CTCTCT concentration Villard et al., 19962 r 3
 .Angiotensinogen A-20C promoter A™C concentration Ishigami et al., 1997
 .1q42-q43
 .C-18T promoter C™T concentration Sato et al., 1997
 .G-6A promoter G™A concentration Inoue et al., 1997
 .  .T174M exon 2 q521 C™T threonine™methionine Jeunemaitre et al., 1992
 .  .M235T exon 2 q704 T™C methionine™ threonine Jeunemaitre et al., 1992
 .Angiotensin II type 1 T-810A promoter T™A ? Poirier et al., 1998
 .receptor 3q21-q25
X  .A1166C 3 UTR A™C receptor sensitivity Bonnardeaux et al., 1994
.  .I Staessen et al., 1997b , angiotensinogen gene M235T
 .Staessen et al., 1999 , and the angiotensin II type 1
 .receptor gene A1166C Bonnardeaux et al., 1994 poly-
morphisms have been extensively investigated in various
populations with a variety of cardiovascular disorders.
Several other polymorphisms, in particular in the promoter
region of the angiotensinogen gene, were also found to be
associated with cardiovascular disease Villard et al., 1996;
Ishigami et al., 1997; Sato et al., 1997; Inoue et al., 1997;
.Jeunemaitre et al., 1992; Poirier et al., 1998 . This review
summarizes the findings on the associations between these
genetic polymophisms and cardiovascular disease.
2. DrI polymorphism of the angiotensin-converting
enzyme gene
The Dr I polymorphism consists of either the absence
or presence of a 287 base-pair DNA fragment, in intron 16
of the angiotensin-converting enzyme gene. It has been
shown to predict approximately half of the inter-individual
variability in the serum Rigat et al., 1990; Tiret et al.,
.  .1992 and tissue Danser et al., 1995 levels of the
angiotensin-converting enzyme. Compared with the II
genotype, the angiotensin-converting enzyme activity was
highest in DD homozygotes and intermediate in ID
heterozygotes. Numerous studies have investigated the re-
lationships between the angiotensin-converting enzyme
gene variants and several cardiovascular–renal disorders,
such as hypertension, myocardial infarction, hypertrophic
cardiomyopathy, and diabetic or non-diabetic nephropathy.
2.1. Pre˝alence of D allele
 .According to a meta-analysis Staessen et al., 1997b of
 .145 studies available in June 1997 on the Dr I polymor-
phism of the angiotensin-converting enzyme gene, the
overall prevalence of the D allele in 49,959 subjects
amounted to 54.0%. The DD, DI and II genotype fre-
quencies were 30.5%, 47.0% and 22.5%, respectively.
Race was a major determinant of the D and I allele
frequencies. The prevalence of the D allele was 56.2% in
 .  .Caucasians, higher P-0.001 in blacks 60.3% , but
 .  .substantially lower P-0.001 in Asians 39.1% .
2.2. D allele and cardio˝ascular disease
2.2.1. Hypertension
In the above-mentioned meta-analysis Staessen et al.,
.1997b , 23 case-control studies were combined. Hyperten-
sion or having a family history of hypertension were not
significantly associated with the D allele. However, there
was a significant heterogeneity among the reports. Com-
pared with the II genotype, DD homozygozity was associ-
ated with a 79% and 61% higher risk of hypertension in
 .two studies in women Gu et al., 1994; Kiema et al., 1996
and in two Japanese Higashimori et al., 1993; Morise et
.  .al., 1994 combined with one Chinese Jian et al., 1996
report, respectively. In all other subgroups, the association
between hypertension and the angiotensin-converting en-
zyme genotype was not statistically significant. Systolic
and diastolic blood pressure data were available in 46
 . studies Staessen et al., 1997b . In all 12,230 subjects 74
.groups and in the subgroup analyses, the blood pressure
levels showed only small and non-significant variations
according to the genotype.
However, two recent population studies O’Donnell et
.al., 1998; Higaki et al., 2000 found that the D allele was
significantly associated with hypertension in men but not
in women. In 3095 Framingham Heart Study participants
 .O’Donnell et al., 1998 , the adjusted odds ratios for
 w xhypertension were 1.59 95% confidence interval CI
.  .1.13–2.23 and 1.18 95% CI 0.87–1.62 for DD and DI
subjects as compared with II homozygotes in men, whereas
in women the corresponding odds ratios were not signifi-
cant. Among 5014 Japanese residents of the city of Suita
 .Higaki et al., 2000 , the frequency of DD homozygosity
was higher in hypertensive men than in their mildly hyper-
tensive or normotensive counterparts 17.1% vs. 11.8%;
.P-0.002 , and the estimated odds ratio for hypertension
 .  .DD vs. II was 1.75 95% CI 1.21–2.53 . The corre-
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sponding odds ratio in women was only 1.17 95% CI
.0.79–1.72 .
2.2.2. Diseases of myocardium
The D allele was also found to be associated with
 .higher risk of electrocardiographic Schunkert et al., 1994
or echocardiographic left ventricular hypertrophy Gharavi
. et al., 1996 , hypertrophic cardiomyopathy Marian et al.,
.  .1993 and idiopathic Raynolds et al., 1993 or ischemic
 .Raynolds et al., 1993 dilated cardiomyopathy. However,
 .in a meta-analysis Staessen et al., 1997b , the overall
excess risk of these diseases in relation to the D allele was
not significant.
 .A further meta-analysis Kuznetsova et al., 2000
specifically derived pooled estimates for the association
between electrocardiographic or echocardiographic left
ventricular hypertrophy and the Dr I polymorphism of the
angiotensin-converting enzyme gene. The study included
28 reports with an overall sample size of 6638 subjects. In
all studies combined, left ventricular hypertrophy was not
associated with the D allele. Compared with the II geno-
type, the excess risks of left ventricular hypertrophy asso-
ciated with DD and DI genotypes were only 14% 95%
. CI 0.92–1.42; Ps0.23 and 5% 95% CI 0.87–1.28;
.Ps0.61 , respectively. However, the sensitivity analysis
showed that in untreated hypertensive patients the DD
genotype, compared with II homozygosity, was associated
 .with a 192% Ps0.002 higher risk of left ventricular
 .hypertrophy Kuznetsova et al., 2000 . Furthermore, if left
ventricular mass was analyzed as a continuous trait across
 .23 studies 5438 subjects , overall no association with the
Dr I polymorphism was present. However, if untreated
hypertensive patients Iwai et al., 1994a,b; Gharavi et al.,
.1996; Pontremoli et al., 1996 were analyzed separately,
echocardiographic left ventricular mass was on average
 .10.1% 95 CI 4.8–15.5%; Ps0.001 higher in DD ho-
mozygotes than in the II reference group. Thus, in un-
treated hypertensive patients, in case-control as well as
association studies, the D allele behaved as a marker for
left ventricular hypertrophy. The findings of this quantita-
 .tive overview Kuznetsova et al., 2000 support the hy-
pothesis that the enhanced angiotensin-converting enzyme
activity associated with the D allele may promote left
ventricular hypertrophy if a pathophysiological process
causing this disorder, remains unopposed by treatment.
2.2.3. Diseases of the large arteries
 .In a landmark study, Cambien et al. 1992 observed an
increased prevalence of the angiotensin-converting enzyme
DD genotype in 610 Caucasian patients with a history of
myocardial infarction. Subsequent studies found that the D
allele was also associated with a higher risk of coronary
 .heart disease Nakai et al., 1994; Beohar et al., 1995 ,
 .stroke Markus et al., 1995; Kario et al., 1996 , other
 .atherosclerotic manifestations Ohishi et al., 1993 , or
having a history of coronary heart disease Tiret et al.,
.1993; Badenhop et al., 1995 .
 .One quantitative overview Staessen et al., 1997b
demonstrated a strong association between atherosclerotic
cardiovascular complications and the Dr I polymorphism
 .of the angiotensin-converting enzyme gene Fig. 1 . In DD
compared with II homozygotes, the excess risk of having
a history of coronary heart disease amounted to 176%. The
excess risk for myocardial infarction was 45%. The risk
associated with the DD genotype was 32% for coronary
heart disease including myocardial infarction. The associa-
tion between the DD genotype and coronary heart disease
was stronger in six Asian studies than in 31 Caucasian
reports. In Asians the DD vs. II odds ratio was 2.73 95%
.CI 2.03–3.67 , whereas in Caucasians it was only 1.29
 .95% CI 1.16–1.44 . The excess risk of stroke in DD vs.
II homozygotes was 94%. For various other athero-
sclerotic manifestations, such as restenosis after angio-
plasty or bypass surgery, renovascular disease, or the
presence of atheroslcerotic plaques or intima-media thick-
ening at level of the carotid or femoral arteries, the excess
risk in DD homozygotes averaged 133%.
Fig. 1. Association between atherosclerotic complications and the D
allele of the angiotensin-converting enzyme gene. DD homozygotes and
the DI heterozygotes were separately contrasted with II homozygotes.
Odds ratios and the corresponding P values are given. CHD, coronary
heart disease. MI, myocardial infarction.
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Three other meta-analyses Samani et al., 1996; Ager-
.holm-Larsen et al., 2000; Keavney et al., 2000 of pub-
lished studies also investigated the association between the
Dr I polymorphism and coronary heart disease. The first
 .meta-analysis Samani et al., 1996 included 15 studies
 .available by September 1995 with nearly 3400 myocar-
dial infarction cases. The odds ratio for myocardial infarc-
tion associated with the DD genotype in comparison with
the ID and II genotypes was 1.26 95% CI 1.15–1.39;
. P-0.0001 . The second meta-analysis Agerholm-Larsen
.et al., 2000 assessed the influence of Dr I polymorphism
on the risk of myocardial infarction and ischemic heart
disease only in Caucasians and differentiated the results in
small studies from those in large groups. In DD compared
with ID and II subjects the overall excess risk was 21%
 .95% CI 11–32%; P-0.001 . However, the excess risk
 .was only shown in small studies 47% but not in large
studies.
The third meta-analysis was recently published along-
side with a large UK study on the association between the
Dr I polymorphism and myocardial infarction Keavney
.et al., 2000 . The analysis also provided combined risk
ratios of carrying the DD genotype in small each with
. fewer 200 myocardial infarction cases and large each
.with 200 to about 1000 cases studies separately. The
combined risk ratio of carrying the DD genotype for cases
vs. controls in 35 small studies was 1.57 99% CI 1.38–
.1.78 , whereas the overall results of 14 larger studies
 .yielded a risk ratio of 0.99 99% CI 0.90–1.08 . In the
 .large UK study Keavney et al., 2000 , the DD genotype
 .was found in 1359 29.4% of 4629 myocardial infarction
 .cases and in 1637 27.6% of 5934 controls. The risk ratio
of carrying the DD genotype in myocardial infarction
cases compared with controls was 1.10 95% CI 1.00–
.1.21 . Similar results were observed in the low-risk sub-
group and in all other strata considered in this report.
2.2.4. Micro˝ascular diseases
The associations between various microvascular disor-
ders and the Dr I polymorphism have also been assessed
Fujisawa et al., 1995; Tarnow et al., 1995; Harden et al.,
1995; Marre et al., 1994; Doria et al., 1994; Nomura et al.,
. 1994; Schmidt et al., 1995 . In two studies Fujisawa et al.,
.1995; Tarnow et al., 1995 diabetic retinopathy was not
associated with the D allele. In contrast, renal diseases
characterized by arteriolar and capillary lesions were more
 .frequently P-0.001 observed in DD than II homozy-
 .gotes Fig. 2 . The combined excess risk of 19 studies
 .averaged 53% Staessen et al., 1997b . The latter observa-
tion could be ascribed to studies on diabetic nephropathy
 .q56% and to reports on nephropathy of mixed origin
 .  .q71% . In studies on immunoglobulin Ig A nephropa-
thy, the risk associated with the DD genotype was not
 . significantly raised q25%; Ps0.24 Staessen et al.,
.1997b .
Fig. 2. Association between microvascular nephropathy and the D allele
of the angiotensin-converting enzyme gene. DD homozygotes and the DI
heterozygotes were separately contrasted with II homozygotes. Odds
ratios and the corresponding P values are given. IgA, immunoglobulin
A.
2.3. Mechanisms of action
Because the Dr I polymorphism is located within in-
tron 16 of the angiotensin-converting enzyme gene, it is
unlikely to exercise any direct effect on angiotensin-con-
verting enzyme activity. Other alleles in linkage disequilib-
rium with the Dr I polymorphism and located within or
near the angiotensin-converting enzyme gene are suspected
to play a role in this regard Tiret et al., 1992; McKenzie
.et al., 1995; Villard et al., 1996 .
There is mounting evidence that increased angiotensin-
converting enzyme gene expression and angiotensin-con-
verting enzyme activity in the vessel wall stimulate the
local rate of angiotensin II production Muller et al., 1997;¨
Schunkert et al., 1990; Okamura et al., 1986; Arnal et al.,
.1994 and in turn, influence tissue function and structure.
On this basis, cardiovascular disease may develop, but
probably only in the presence of disruption of systemic
compensatory mechanisms due to long-term exposure to
other risk factors. This probably explains why the DD
homozygotes have a higher risk of hypertension only in
men, have excess risk of left ventricular hypertrophy only
in untreated hypertensive patients, or have an increased
risk of nephropathy in the presence of diabetes or other
concomitant diseases. In addition, gene–gene interactions
may also be important for the development of cardio-
vascular disorders, which usually have a multi-factorial
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etiology. One study showed synergistic effects of the
angiotensin-converting enzyme D r I and a-adducin
Gly460Trp polymorphism on the blood pressure response
 .to sodium loading Barlassina et al., 2000 . In GlyrGly
homozygotes the increase in blood pressure was similar
across the angiotensin-converting enzyme Dr I genotypes,
whereas in carriers of Trp allele it was positively and
linearly associated with the angiotensin-converting enzyme
D allele. Moreover, several studies observed a synergistic
effect of the angiotensin-converting enzyme Dr I and
angiotensin II type 1 receptor A1166C polymorphism on
the risk of coronary heart disease Tiret et al., 1994;
´ .Alvarez et al., 1998; Fatini et al., 2000 .
3. M235T angiotensinogen gene polymorphism
In humans, the angiotensinogen gene is located on
chromosome 1q42-43 and comprises five exons and four
introns spanning 12 kb Gaillard et al., 1989; Jeunemaitre
. et al., 1997 . Of nearly 20 molecular variants Jeunemaitre
.et al., 1992, 1997 , one polymorphism encodes threonine
 .instead of methionine M235T . Several studies have in-
vestigated the relationships between cardiovascular disor-
ders and the M235T variant of the angiotensinogen gene.
3.1. Pre˝alence of the T allele
 .In 69 studies published before April, 1998 , the overall
prevalence of the T allele was 52.1% Staessen et al.,
.1999 . The TT , TM and MM genotype frequencies were
30.6%, 42.9% and 26.5%, respectively. The prevalence of
 .the T allele was dependent on race P-0.001 . It was
77.0% in blacks, 78.0% in Asians, but only 42.2% in
whites.
3.2. T allele and cardio˝ascular disease
3.2.1. Hypertension
In a study involving two genetically distinct populations
in Salt Lake City and Paris, the T allele was significantly
more frequent in hypertensive patients than in controls
 .Jeunemaitre et al., 1992 . The prevalence of the T allele
was 36% in controls, 47% in unrelated index cases, and
51% in severely hypertensive patients. Moreover, TT ho-
mozygotes had approximately 20% higher concentrations
of plasma angiotensinogen.
In a meta-analysis of 32 case-control studies Staessen
.et al., 1999 , hypertension or having a history of hyper-
 .tension Nishiuma et al., 1995 were significantly associ-
 .ated with the T allele Fig. 3 . Compared with MM
Fig. 3. Association between hypertension and the T allele of the angiotensinogen gene. TT homozygotes and the TM heterozygotes were separately
contrasted with MM homozygotes. Odds ratios are given.
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homozygotes, the TT and TM genotypes had a 31% Ps
.  .0.001 and 11% Ps0.03 excess risk. However, if differ-
ent races were considered separately, the association with
hypertension was only significant in Caucasians Staessen
. et al., 1999 , but not in Asians Iwai et al., 1994a,b;
Nishiuma et al., 1995; Chiang et al., 1997; Sato et al.,
. 1997 and blacks Rotimi et al., 1994, 1997; Caulfield et
.al., 1995; Borecki et al., 1997 .
 .Another meta-analysis Kunz et al., 1997 reviewed the
frequency of T allele with respect to hypertension in
studies in Caucasians published between 1992 and 1996.
In all 5493 subjects, the common odds ratio associated
with the T allele, compared with the M variant, was 1.20
 .95% CI 1.11–1.29; P-0.0001 . The odds ratio increased
 .to 1.42 95% CI 1.25–1.61 in subjects with a positive
family history of hypertension and to 1.39 95% CI 1.20–
.1.62 in hypertensive patients recruited from referral cen-
 .ters. In a meta-analysis Kato et al., 1999 restricted to
seven Japanese studies with a total of 1228 hypertensive
cases and 1121 controls, the odds ratio associated with T
 .allele was 1.2 95% CI 1.0–1.4 .
3.2.2. Cardiomyopathy
In a Japanese study on hypertrophic cardiomyopathy
 .Ishanov et al., 1997 , the T allele frequency was higher in
patients with sporadic hypertrophic cardiomyopathy than
in unaffected siblings and offspring 88% vs. 78%; P-
.0.05 . The T allele frequency among the latter subjects
 .was similar to that observed in healthy people 78% . In
 .another Japanese study Yamada et al., 1997 , the preva-
lence of the T allele was not different between patients
with nonfamilial hypertrophic or dilated cardiomyopathy
and healthy controls. Two studies combined Yamada et
.al., 1997; Ishanov et al., 1997 hypertrophic and dilated
cardiomyopathy were not significantly associated with the
M235T polymorphism. In TT and TM subjects compared
with MM homozygotes, the odds ratios were 0.91 and
 .0.76, respectively Staessen et al., 1999 .
3.2.3. Atheroslerotic complications
Several studies Katsuya et al., 1995, 1996; Ishigami et
.al., 1995 demonstrated a significant association between
coronary heart disease and the M235T polymorphism.
However, in 12 studies combined, the T allele was not
associated with atherosclerotic cardiovascular complica-
 .tions Staessen et al., 1999 . The pooled excess risk of
 .17% Ps0.08 in TT vs. MM homozygotes did not
exceed the threshold of statistical significance in nine
reports on coronary heart disease, including myocardial
infarction. Similarly, for stroke and various other athero-
sclerotic manifestations, such as restenosis after angio-
plasty or the presence of atherosclerotic lesions Kamitani
.et al., 1995; McLaughlin et al., 1995 , there was no excess
risk in TT homozygotes compared with MM homozy-
gotes.
3.2.4. Micro˝ascular disease
Diabetic retinopathy in three studies and renal diseases
characterized by arteriolar or capillary lesions in 13 studies
were not associated with the T allele Staessen et al.,
.1999 . In TT compared with MM homozygotes, the com-
 .bined odds ratios were 1.16 95% CI 0.76–1.77; Ps0.49
for diabetic retinopathy and 1.15 95% CI 0.95–1.38;
.Ps0.15 for microvascular renal diseases.
3.3. Mechanisms of action
Several mechanisms may explain the significant associ-
ation between hypertension and the M235T polymor-
phism. First, the large amount of angiotensinogen in the
circulation does not constitute an excess substrate for renin
 .cleavage Bohlender et al., 1996; Caulfield et al., 1996 .
Accordingly, an increase in the angiotensinogen concentra-
tion will lead to increased angiotensin I generation, even if
the plasma renin concentration does not change Bohlender
.et al., 1996; Caulfield et al., 1996 . Second, in gene
titration experiments in mice Kim et al., 1995; Inoue et
.  .al., 1997; Smithies, 1997 or rats Bohlender et al., 1996 ,
the plasma angiotensinogen concentration rose progres-
sively, although not linearly, from zero in the zero copy
animals to 145% of normal in four-copy animals
Bohlender et al., 1996; Inoue et al., 1997; Smithies,
.1997 . Increased angiotensinogen gene expression also
causes hypertension Bohlender et al., 1996; Kim et al.,
.1995; Smithies, 1997 . Third, recent studies have shown
that the human angiotensinogen gene promoter element 1,
X located in the 5 upstream core promoter region position
.y25 to y1 , plays an important role in the expression of
angiotensin mRNA by binding with the transcription factor
Fukamizu et al., 1989; Tamura et al., 1994; Yanai et al.,
. 1996 . Mutations in this area, such as the A-20C Ishigami
.  .et al., 1997 and G-6A Inoue et al., 1997 base-pair
substitutions, are in almost complete linkage disequilib-
rium with the M235T variant in exon 2 of the an-
 .giotensinogen gene Jeunemaitre et al., 1997 . Recent hu-
man studies showed a significant correlation of the G-6A
 . Jeunemaitre et al., 1997 and A-20C Ishigami et al.,
.1997 variants with the plasma angiotensinogen concentra-
 .tion Ishigami et al., 1997 and essential hypertension
 .Jeunemaitre et al., 1997; Ishigami et al., 1997 .
4. A1166C polymorphism of the angiotensin II type 1
receptor gene
An A™C transversion at nucleotide position 1166 was
located in the 3X untranslated region of the angiotensin II
 .  .type 1 receptor gene Table 1 Bonnardeaux et al., 1994 .
Several studies have shown that it was associated with
 .hypertension Bonnardeaux et al., 1994 , left ventricular
 .hypertrophy Takami et al., 1998 , coronary heart disease,
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 .myocardial infarction Tiret et al., 1994 , and progression
 .of diabetic nephropathy Tomino et al., 1999 .
4.1. Pre˝alence of the C allele
The overall frequency of the C allele in 13 studies
 .published before November, 1996 with 4332 subjects
 .was 25.7% Staessen et al., 1997a . The prevalence of the
 . C allele 28.8% vs. 9.2% , CC homozygosity 7.7% vs.
.  .1.1% and CA heterozygosity 42.1% vs. 16.2% was
 .significantly higher in Caucasians than Asians P-0.001 .
4.2. The C allele and cardio˝ascular disease
4.2.1. Hypertension
In a case-control study on hypertension in white people,
the frequency of the C allele was significantly higher in
206 hypertensive patients than in 298 normotensive sub-
 .  .jects 36% vs. 28%; P-0.01 Bonnardeaux et al., 1994 .
The finding was confirmed by two Wang et al., 1997;
. Miyamoto et al., 1996 of three Wang et al., 1997;
.Miyamoto et al., 1996; Takami et al., 1998 subsequent
case-control studies. The frequencies of the C allele and
the CC genotype in 108 Caucasian hypertensive patients
with a family history of hypertension were significantly
higher than in 84 normotensive controls Wang et al.,
.1997 . In CC homozygotes compared with AC and AA
subjects combined, the odds ratio for hypertension was 7.3
 .95% CI 1.9–31.9 . The prevalence of the C allele was
higher in 90 Japanese hypertensive patients than in 89
 .normotensive controls 11.7% vs. 3.9%; P - 0.001
 .Miyamoto et al., 1996 . No significant association be-
tween hypertension and the C allele was observed in
another Japanese study that included 321 hypertensive
 .cases and 215 control subjects Takami et al., 1998 . The
frequency of the C allele was similar in both groups. In
addition, both systolic and diastolic blood pressures were
not significantly different across the A1166C genotypes
 .Takami et al., 1998 .
Three association studies on the A1166C polymor-
phism considered blood pressure as a continuous trait
Hingorani et al., 1995; Castellano et al., 1996; Zhang et
.al., 2000 . The results of these studies were not consistent.
In an Italian study of 125 previously untreated hyperten-
 .sive patients Hingorani et al., 1995 , both systolic and
diastolic blood pressure were positively and linearly asso-
ciated with the number of C alleles after accounting for
sex, age, body mass index, alcohol intake, and the M235T
polymorphism of the angiotensinogen gene. Among 212
subjects randomly selected from a general population in
 .northern Italy Castellano et al., 1996 , clinic systolic and
diastolic blood pressures were on average 11.3 mm Hg
 .  .Ps0.005 and 4.2 mm Hg Ps0.01 lower in CC
homozygotes than AC heterozygotes and AA homozy-
gotes. Ambulatory blood pressure was similar across the
A1166C genotypes. In 548 German participants in the
MONICA Monitoring Trends and Determinants in Car-
.  .diovascular Disease study Zhang et al., 2000 , the preva-
lence of CC homozygosity was only 5% and both blood
pressure levels and the prevalence of hypertension were
not related to the A1166C polymorphism.
4.2.2. Diseases of myocardium
Several studies examined the association between the
A1166C polymorphism and left ventricular hypertrophy
Castellano et al., 1996; Hamon et al., 1997; Takami et al.,
.  .1998 , or hypertrophic Osterop et al., 1998 or dilated
 .cardiomyopathy Tiret et al., 2000 . In 61 Japanese nor-
motensive subjects—but not in 110 hypertensive patients
—the C allele was associated with a greater left ventricu-
lar wall thickness, intraventricular septum, and left ventric-
 .  .ular mass index P-0.05 Takami et al., 1998 . How-
ever, these results were not confirmed by two studies in
 .Caucasians Castellano et al., 1996; Hamon et al., 1997 .
In a study of 104 genetically independent subjects with
hypertrophic cardiomyopathy, the C allele was associated
 .with a higher left ventricular mass Osterop et al., 1998 .
 . 2The left ventricular mass index was 190"8 S.E. grm
in subjects carrying the C allele and 168"7 grm2 in AA
 .homozygotes Ps0.01 . Using the case-control approach,
the C allele was not significantly associated with the risk
or the severity of the idiopathic dilated cardiomyopathy
 .Tiret et al., 2000 .
4.2.3. Atherosclerotic complications
At least three studies observed synergistic effects of the
angiotensin-converting enzyme Dr I and the angiotensin
II type 1 receptor A1166C polymorphisms on the risk of
 .myocardial infarction Tiret et al., 1994 or coronary heart
´ .disease Alvarez et al., 1998; Fatini et al., 2000 . In a
case-control study of 613 myocardial infarction cases and
 .723 age-matched population controls Tiret et al., 1994 ,
the odds ratio associated with the angiotensin-converting
 .enzyme DD genotype was 1.05 95% CI 0.75–1.49 in
subjects without the C allele of the angiotensin II type 1
 .receptor gene, 1.52 95% CI 1.06–2.18 in AC hetero-
 .zygotes and 3.95 95% CI 1.26–12.4 in CC homozygotes
 .test for trend P-0.02 . Another study included 181
patients younger than 50 years who had a history of
myocardial infarction or unstable angina and 240 controls
from the same homogeneous Caucasian population in
´ .northern Spain Alvarez et al., 1998 . The odds ratio for
coronary heart disease associated with the DD genotype
 .was 5.32 95% CI 1.45–19.51; Ps0.02 in CC homozy-
 .gotes and only 1.01 95% CI 0.33–5.39; Ps0.31 in
carriers of A allele. More recently, an Italian study re-
cruited 205 patients with a history of myocardial infarction
or angina pectoris and with angiographically documented
 . coronary artery stenosis )75% and 209 controls Fatini
.et al., 2000 . After accounting for hypertension, body mass
index, diabetes, dyslipidemia and smoking, the odds ratios
for coronary heart disease associated with the angiotensin-
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converting enzyme DD, the angiotensin II type 1 receptor
 . CC, and both genotypes were 1.81 Ps0.01 , 2.61 Ps
.  .0.01 , and 4.02 P-0.0001 , respectively.
Synergistic effects of the angiotensin-converting en-
zyme D and the angiotensin II type 1 receptor C allele
were also observed for malignant ventricular arrhythmias
in patients with coronary heart disease and for a history of
malignant ventricular arrhythmias treated by an im-
 .plantable cardioverter defibrillator Anvari et al., 1999 .
The odds ratio for malignant ventricular arrhythmias was
2.4 per number of DrC alleles 95% CI 1.41–3.94,
.P-0.001 . The angiotensin II type 1 receptor C allele
was also found to be associated with coronary atheroma
 .Rice et al., 1999 , the development of coronary artery
 .stenosis Nakauchi et al., 1996 , or the number of lacunae
 .in the brain Takami et al., 2000 .
Benetos et al. in a French population found that the C
allele was associated with higher pulse wave velocity in
 .hypertensive patients Benetos et al., 1995, 1996b , but not
 .in normotensive subjects Benetos et al., 1996b . The C
allele was also associated with the magnitude of change in
pulse wave velocity produced by antihypertensive drug
 .treatment Benetos et al., 1996a . An angiotensin-convert-
 .ing enzyme inhibitor perindopril reduced pulse wave
velocity more in carriers of the C allele than in AA
homozygotes, whereas a calcium-channel blocker
 .nitrendipine decreased pulse wave velocity only in AA
homozygotes. However, also in a French population, Gir-
 .erd et al. 1998 failed to demonstrate a significant associa-
tion between the wall thickness of the radial and carotid
arteries and the A1166C polymorphism.
4.2.4. Micro˝ascular complications
Studies on nephropathy were not consistent Hunley et
al., 1996; Tarnow et al., 1996; Marre et al., 1997; Yudkin
.et al., 1997; Tomino et al., 1999 . Only a Japanese study
found that in a sample of 114 non-insulin-dependent dia-
betic female patients with overt albuminuria, the C allele
was associated with a higher risk of renal insufficiency
 .Tomino et al., 1999 . Other studies did not show any
evidence for the association between the A1166C poly-
morphism and susceptibility or progression of renal dis-
eases characterized by arteriolar or capillary lesions in
subjects with diabetes Tarnow et al., 1996; Marre et al.,
.  .1997 , microalbuminuria Yudkin et al., 1997 , or IgA
 .  .immunoglobulin A nephropathy Hunley et al., 1996 .
4.3. Mechanisms of action
The associations between cardiovascular disease and the
A1166C polymorphism in the angiotensin II type 1 recep-
tor gene are thought to be due to linkage disequilibrium
with other polymorphisms in the angiotensin II type 1
receptor gene or in other genes. Indeed, several studies
observed an epistatic interaction between the angiotensin-
converting enzyme Dr I and the angiotensin II type 1
´receptor A1166C polymorphism Tiret et al., 1994; Alvarez
.et al., 1998; Fatini et al., 2000 .
Two recent studies have revealed an association be-
tween the A1166C polymorphism and the sensitivity of
the angiotensin II type 1 receptor in human vessels Amant
.et al., 1997; van Geel et al., 2000 . In 140 patients with
normal coronary arteries, 13 CC homozygotes had signifi-
cantly greater vasoconstriction in distal coronary vessels in
response to methylergonovine maleate injection P-
.  .0.009 Amant et al., 1997 . In line with this finding,
another study demonstrated that the C allele was associ-
ated with an increased vasoreactivity to angiotensin II in
 .human arteries van Geel et al., 2000 . The enhanced
vasoconstriction associated with the A1166C polymor-
phism may partially account for the higher blood pressure
 .in C allele bearers Bonnardeaux et al., 1994 . The same
mechanism may directly contribute to the excess risk of
myocardial infarction and angina pectoris in carriers of C
allele.
5. Other gene polymorphisms in the renin–angiotensin
system
( )5.1. 4656 CT polymorphism of the angiotensin-con-2r 3
˝erting enzyme gene
( )The 4656 CT polymorphism of the angiotensin-2r 3
converting enzyme gene depends on a repetition of two or
 .  .three CT nucleotides Table 1 Villard et al., 1996 . In
parents of 95 healthy nuclear families, after adjustment for
the angiotensin-converting enzyme Dr I variant, the
( )4656 CT polymorphism was still associated with serum2r 3
 .angiotensin-converting enzyme levels Ps0.04 . This
polymorphism has not yet been found to be associated
with any cardiovascular disease.
5.2. Other polymorphisms of the angiotensinogen gene
5.2.1. T174M angiotensinogen gene polymorphism
The T174M polymorphism is in complete linkage dise-
 .quilibrium with the M235T variant P - 0.0001
 .Jeunemaitre et al., 1992 ; 174M allele is present in a
subset of chromosomes carrying the 235T allele. The
overall frequency of the M allele of the T174M variant in
12 studies with 4952 subjects was 11.0% Staessen et al.,
.1997a . The MM homozygotes made up 1.2% of all
subjects examined. Race was a major determinant of the M
allele frequencies, which was similar among Caucasians
 .  .12.9% and Asians 10.9% , but which was as low as
6.0% in blacks P-0.001 for difference with the other
.races .
The T174M polymorphism was also associated with
 .hypertension Jeunemaitre et al., 1992 and examined for
association with other cardiovascular disorders Marre et
.al., 1997 . However, this polymorphism did not provide
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more informative evidence over and above the M235T
variant.
5.2.2. A-20C, C-18T and G-6A polymorphisms in the
promoter region of the angiotensinogen gene
A cis-acting DNA element located between the TATA
box and the transcription initiation site is critical in the
response to the regulatory sequence in angiotensinogen
 .gene Yanai et al., 1996 . Sequence difference in this
angiotensinogen core promotor element 1 at y25 to y1
.base region upstream from transcriptional initiation site
alters the binding affinity of a ubiquitous transcriptional
factor, angiotensinogen core promotor element binding
 .factor 1. When three haplotypes at y20 to y18 in the
angiotensinogen core promotor element 1 were compared,
CTC and ATC showed 2.5 times higher transcriptional
activity than ATT. Furthermore, recent transfection data
show that a human angiotensinogen gene promoter con-
taining the y20C mutation transcribes a reporter gene at a
 .greater level than the y20A Zhao et al., 1999 . Therefore,
the A-20C polymorphism may also affect transcription
activity of angiotensinogen mRNA in humans and hence
alter the plasma angiotensinogen level.
The A-20C and M235T variants are in close linkage
 .disequilibrium Sato et al., 1997 . The frequency of the
 .y20C allele was 27% in Japanese Ishigami et al., 1997
and 19% and 14% in Caucasian hypertensive patients and
normotensive controls, respectively Jeunemaitre et al.,
.1992 . In Japanese, the y20C allele was reported to be
associated with a higher level of plasma angiotensinogen
 .Ishigami et al., 1997, 1999 and a higher risk of hyper-
 .tension Ishigami et al., 1997 . However, the findings were
not confirmed by other investigators Sato et al., 1997;
.Jeunemaitre et al., 1992, 1997 .
The frequency of the y18T allele was 1% and 4% in
Japanese hypertensive patients and normotensive controls
 .Sato et al., 1997 , respectively, and 13% in Caucasian
 .people Jeunemaitre et al., 1992 . The C-18T polymor-
phism was associated with hypertension in Japanese Sato
. et al., 1997 , but not in Caucasians Jeunemaitre et al.,
.1992 . In the Japanese study, the odds ratio for hyper-
tension in CC homozygotes compared with carriers of the
 .T allele was 4.2 95% CI 1.4–12.8; P-0.005 .
The y6A allele of the G-6A polymorphism of the
angiotensinogen gene was associated with a greater in-vitro
angiotensinogen gene transcription and expression Inoue
.et al., 1997 . This apparently functional polymorphism is
in nearly complete disequlibrium with the M235T locus.
The y6A allele was associated with higher blood pressure
in a cross-sectional study of 274 Japanese outpatients
 .Ishigami et al., 1999 and also associated with a higher
risk of hypertension in a case-control study involving both
 .Caucasian and Japanese subjects Jeunemaitre et al., 1997 .
Among 1509 participants in the Trials of Hypertension
Prevention study, AA homozygotes in the usual care group
 .had a higher 3-year incidence rate of hypertension 44.6%
 .  .than GG homozygotes 31.5% Hunt et al., 1998 . The
relative risk was 1.4 95% CI 0.87–2.34; test for trend
.across all three genotypes Ps0.10 . After dietary sodium
restriction, the incidence of hypertension was significantly
lower in AA homozygotes relative risk vs. usual care
.0.57, 95% CI 0.34–0.98 , but not in GG homozygotes
relative risk 1.2, 95% CI 0.79–1.81; test for trend Ps
.0.02 . For the effects of weight loss on hypertension
incidence, the trends across genotypes were similar to
those for sodium restriction. Therefore, the angiotensino-
gen G-6A polymorphism may affect blood pressure re-
sponse to sodium or weight reduction and the development
of hypertension. However, the NHLBI National Heart
.Lung Blood Institute Family Blood Pressure Program
showed that the G-6A polymorphism had minimal to no
effect on the inter-individual variation of blood pressure in
Caucasians, African Americans and Asians Province et
.al., 2000 .
5.3. T-810A polymorphism of the angiotensin II type 1
receptor gene
Among many polymorphisms identified in the an-
giotensin II type 1 receptor gene, the T-810A locus may be
 .associated with myocardial infarction Poirier et al., 1998 .
The y810A allele frequency was significantly lower in
631 Caucasian myocardial infarction cases than in 725
 .controls 15% vs. 18%; P-0.05 . The odds ratio associ-
ated with the y810A allele for myocardial infarction was
 .0.80 95% CI 0.65–0.97 . In the same study, this polymor-
phism was not associated with blood pressure.
6. Conclusions and discussions of future research
Genetic studies of the components of the renin–angio-
tensin system produced evidence that several genetic poly-
morphisms, acting alone or in concert, may behave as
markers of various cardiovascular disorders. Further stud-
ies on the pathogenetic mechanisms linking these genetic
variants and cardiovascular disease are of paramount im-
portance. A large number of patients with hypertension,
myocardial infarction, or congestive heart failure are cur-
rently on treatment with angiotensin-converting enzyme
inhibitors or angiotensin II type 1 receptor antagonists. The
efficacy of these drugs across different genotypes should
also be investigated in terms of blood pressure reduction as
well as prevention of mortality and morbidity.
Several lessons can be drawn from the present review in
terms of the preferable directions of future research pro-
jects. First, more attention should be paid to the standard-
ization of the phenotype, especially for continuous and
highly variable traits, such as blood pressure. Second,
more energy should be invested in the definition of inter-
mediary phenotypes, which can be easily measured on a
large scale and which may link genes of interest to disease
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outcomes. Paradigms, such as for instance the role of the
angiotensin-converting enzyme and angiotensinogen in the
pathogenesis of atherosclerosis or hypertension, respec-
tively, should also be developed for other genes and other
diseases. Third, polygenic disorders arise through interac-
tion between genetic predisposition, lifestyle and environ-
mental factors. Thus, future studies should not only have
sufficient sample size to detect small genetic effects, but
should also consider gene–gene interaction Frankel and
.Schork, 1996 and interaction between genetic background
and other environmental factors. Fourth, the genetic factors
involved in chronic illnesses are likely to differ across
races, because of the varying frequencies of alleles and
genotypes. Such important information may be drawn from
the investigation and comparison of racially homogeneous
populations, using strictly standardized epidemiological
methods. Along these lines, a population-based study of
nuclear families is currently being conducted in Gaoping
City, near Beijing, in the People’s Republic of China in the
framework of the collaboration between the Chinese and
Flemish governments. The epidemiological and genetic
techniques used in this Chinese study are the same as those
employed in other population studies in Belgium Staessen
.et al., 2000 and Europe. It is to be expected that compara-
tive genetic studies may offer a new and informative
approach to polygenic diseases, such as hypertension and
atherosclerosis.
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